nach oben

Current Obstetrics and Gynecology Reports

Erschienen in:

19.05.2023 | REVIEW

An Update on Contraception for Transgender, Non-binary, and Gender-expansive Individuals

verfasst von: Kelsey Mumford, Alexis Light

Erschienen in: Current Obstetrics and Gynecology Reports | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The goal of this review is to summarize the current understanding of how exogenous testosterone and estrogen affects fertility in transgender, non-binary, and gender-expansive (TGE) individuals, and what contraceptive options are available for this population.

Recent Findings

Recent studies have shown conflicting findings with regards to the effects of exogenous testosterone on ovulation and the endometrium; however, the overarching conclusion continues to be that it cannot be viewed as a contraceptive. Survey studies conducted in the past 5 years have repeatedly shown disparities in the rates of contraceptive use among TGE individuals compared to their cisgendered peers, with condoms being the most commonly used contraceptive among this population, followed by the pill and long-acting reversible contraceptives. Studies on the effects of exogenous estrogen use on testicular structure and spermatogenesis have shown findings suggestive of reduced fertility; however, no long-term data is available and further investigation is needed. Contraceptives need to be recommended for these individuals to avoid unintended pregnancies due to incomplete suppression of spermatogenesis. Data shows condoms are the first-line option.

Summary

Despite the need for healthcare providers to discuss contraception with TGE individuals, research and guidance on this topic remains limited. Advancements have been made in understanding how exogenous testosterone or estrogen taken as part of gender-affirming hormone therapy (GAHT) can affect fertility, but there remain significant gaps in knowledge beyond the understanding that these therapies are not sufficient to prevent pregnancy and contraception is required to avoid unintended pregnancies. There remain disparities in contraceptive use among TGE individuals, and between TGE individuals and their cisgendered peers. This literature review will focus primarily on new publications related to the contraceptive needs and options for the TGE community to help inform healthcare providers of specific considerations for their TGE patients. By creating a trusting, gender-inclusive environment, reproductive healthcare providers can engage in shared decision-making with TGE patients to select the most appropriate contraceptive for each specific patient.

Coleman E, Radix AE, Bouman WP, et al. Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgend Health. 2022;23(Suppl 1):S1-S259. Published 2022 Sep 6. https://doi.org/10.1080/26895269.2022.2100644.

Rafferty J, Yogman M, Baum R, et al. Ensuring comprehensive care and support for transgender and gender-diverse children and adolescents. Pediatrics. 2018 Oct 1;142(4). https://doi.org/10.1542/peds.2018-2162.

•• Bonnington A, Dianat S, Kerns J, et al. Society of Family Planning clinical recommendations: contraceptive counseling for transgender and gender diverse people who were female sex assigned at birth. Contraception. 2020;102(2):70–82. https://doi.org/10.1016/j.contraception.2020.04.001. This recent clinical guidance by the Society of Family Planning outlines special considerations that providers should consider when providing contraceptive counseling for TGE individuals, based on available literature and expert opinions.CrossRefPubMed

Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society Clinical Practice Guideline [published correction appears in J Clin Endocrinol Metab. 2018 Feb 1;103(2):699] [published correction appears in J Clin Endocrinol Metab. 2018 Jul 1;103(7):2758–2759]. J Clin Endocrinol Metab. 2017;102(11):3869–3903. https://doi.org/10.1210/jc.2017-01658.

Rosen HN, Hamnvik OR, Jaisamrarn U, et al. Bone densitometry in transgender and gender non-conforming (TGNC) individuals: 2019 ISCD official position. J Clin Densitom. 2019;22(4):544–53. https://doi.org/10.1016/j.jocd.2019.07.004.CrossRefPubMed

Thompson J, Hopwood RA, de Normand S, Cavanaugh T. Medical care of trans and gender diverse adults. March 2021. Fenway Health, Boston, MA. https://fenwayhealth.org/wp-content/uploads/Medical-Care-of-Trans-and-Gender-Diverse-Adults-Spring-2021-1.pdf.

Light AD, Obedin-Maliver J, Sevelius JM, Kerns JL. Transgender men who experienced pregnancy after female-to-male gender transitioning. Obstet Gynecol. 2014;124:1120–7.CrossRefPubMed

Pelusi C, Costantino A, Martelli V, Lambertini M, Bazzocchi A, Ponti F, et al. Effects of three different testosterone formulations in female-to-male transsexual persons. J Sex Med. 2014;11:3002–11.CrossRefPubMed

Light AD, Wang L-F, Zeymo A, Gomez-Lobo V. Family planning and contraception use in transgender men. Contraception. 2018;98:266–9.CrossRefPubMed

10.

Schubert FD, Carey JM. Data unclear on pregnancy risk in transmasculine individuals on testosterone. Am J Obstet Gynecol. 2020;222:393–4.CrossRefPubMed

11.

Spinder T, Spijkstra JJ, van den Tweel JG, Burger CW, van Kessel H, Hompes PG, et al. The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects. J Clin Endocrinol Metab. 1989;69:151–7.CrossRefPubMed

12.

De Roo C, Lierman S, Tilleman K, Peynshaert K, Braeckmans K, Caanen M, et al. Ovarian tissue cryopreservation in female-to-male transgender people: insights into ovarian histology and physiology after prolonged androgen treatment. Reprod Biomed Online. 2017;34:557–66.CrossRefPubMed

13.

Deutsch MB, Bhakri V. Kubicek K Effects of cross-sex hormone treatment on transgender women and men. Obstet Gynecol. 2015;125:605–10.CrossRefPubMedPubMedCentral

14.

Perrone AM, Cerpolini S, Maria Salfi NC, Ceccarelli C, Badiali de Giorgi L, Formelli G et al. Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals. J Sex Med. 2009;6:3193–200.

15.

Caanen MR, Soleman RS, Kuijper EA, Kreukels BPC, De Roo C, Tilleman K, et al. Antimullerian hormone levels decrease in female-to-male transsexuals using testosterone as cross-sex therapy. Fertil Steril. 2015;103:1340–5.CrossRefPubMed

16.

Taub RL, Ellis SA, Neal-Perry G, Magaret AS, Prager SW, Micks EA. The effect of testosterone on ovulatory function in transmasculine individuals. Am J Obstet Gynecol. 2020;S0002–9378:30134–44.

17.

Grimstad FW, Fowler KG, New EP, Ferrando CA, Pollard RR, Chapman G, et al. Uterine pathology in transmasculine persons on testosterone: a retrospective multicenter case series. Am J Obstet Gynecol. 2019;220(257):e1-257.e7.

18.

Loverro G, Resta L, Dellino M, Di Naro E, Cascarano MA, Loverro M, et al. Uterine and ovarian changes during testosterone administration in young female-to-male transsexuals. Taiwan J Obstet Gynecol. 2016;55:686–91.CrossRefPubMed

19.

Hawkins M, Deutsch MB, Obedin-Maliver J, et al. Endometrial findings among transgender and gender nonbinary people using testosterone at the time of gender-affirming hysterectomy. Fertil Steril. 2021;115(5):1312–7. https://doi.org/10.1016/j.fertnstert.2020.11.008.CrossRefPubMed

20.

Schwartz AR, Russell K, Gray BA. Approaches to vaginal bleeding and contraceptive counseling in transgender and gender nonbinary patients. Obstet Gynecol. 2019;134:81–90.CrossRefPubMed

21.

Abern L, Maguire K. Contraception knowledge in transgender individuals: are we doing enough? Obstet Gynecol. 2018;131:65S.CrossRef

22.

Stark B, Hughto JMW, Charlton BM, Deutsch MB, Potter J, Reisner SL. The contraceptive and reproductive history and planning goals of trans-masculine adults: a mixed-methods study. Contraception. 2019;100:468–73.CrossRefPubMedPubMedCentral

23.

• Crissman HC, Stroumsa D, Tilea A, Moravek MB, Harris LH, Dalton VK. Leveraging administrative claims to understand disparities in gender minority health: Contraceptive use patterns among transgender and nonbinary people. LGBT Health. 2022;9(3):186–93. https://doi.org/10.1089/lgbt.2021.0303. Findings from this study suggest that transmasculine people are being prescribed fewer oral contraceptive pills and less long-acting reversible contraceptives, have more hysterectomies, and are less likely to use any contraceptive at all when compared to cisgender women.CrossRefPubMed

24.

Agénor M, Cottrill AA, Kay E, Janiak E, Gordon AR, Potter J. Contraceptive beliefs, decision making and care experiences among transmasculine young adults: a qualitative analysis. Perspect Sex Reprod Health. 2020;52(1):7–14. https://doi.org/10.1363/psrh.12128.CrossRefPubMed

25.

Fix L, Durden M, Obedin-Maliver J, et al. Stakeholder perceptions and experiences regarding access to contraception and abortion for transgender, non-binary, and gender-expansive individuals assigned female at birth in the U.S. Arch Sex Behav. 2020;49(7):2683–2702. https://doi.org/10.1007/s10508-020-01707-w.

26.

Nahata L, Chen D, Quinn GP, et al. Reproductive attitudes and behaviors among transgender/nonbinary adolescents. J Adolesc Health. 2020;66(3):372–4. https://doi.org/10.1016/j.jadohealth.2019.09.008.CrossRefPubMed

27.

Forsberg H, Eliason MJ. Healthcare providers’ pregnancy prevention counseling of trans and non-binary assigned female at birth (TNB/AFAB) patients. J Homosex. 2022;69(2):356–83. https://doi.org/10.1080/00918369.2020.1819713.CrossRefPubMed

28.

Unger CA. Care of the transgender patient: a survey of gynecologists’ current knowledge and practice. J Womens Health (Larchmt). 2015;24(2):114–8. https://doi.org/10.1089/jwh.2014.4918.CrossRefPubMed

29.

Marshall Z, Welch V, Minichiello A, Swab M, Brunger F, Kaposy C. Documenting research with transgender, nonbinary, and other gender diverse (trans) individuals and communities: introducing the global trans research evidence map. Transgend Health. 2019;4(1):68–80. Published 2019 Mar 1. https://doi.org/10.1089/trgh.2018.0020.

30.

Cipres D, Seidman D, Cloniger C, Nova C, O’Shea A, Obedin-Maliver J. Contraceptive use and pregnancy intentions among transgender men presenting to a clinic for sex workers and their families in San Francisco. Contraception. 2017;95:186–9.CrossRefPubMed

31.

Mancini I, Alvisi S, Gava G, Seracchioli R, Meriggiola MC. Contraception across transgender. Int J Impot Res. 2020;33(7):710–9. https://doi.org/10.1038/s41443-021-00412-z.CrossRefPubMed

32.

Baillargeon J, Urban RJ, Morgentaler A, Glueck CJ, Baillargeon G, Sharma G, et al. Risk of venous thromboembolism in men receiving testosterone therapy. Mayo Clin Proc. 2015;90:1038–45.CrossRefPubMed

33.

Shatzel JJ, Connelly KJ, DeLoughery TG. Thrombotic issues in transgender medicine: a review. Am J Hematol. 2017;92:204–8.CrossRefPubMed

34.

Fan EM, Gordner C, Luty J. Venous thromboembolism in a transgender adolescent on testosterone therapy: a case report and literature review. J Pediatr Hematol Oncol. 2020;42(5):e352–4. https://doi.org/10.1097/MPH.0000000000001755.CrossRefPubMed

35.

LaVasseur C, Neukam S, Kartika T, Samuelson Bannow B, Shatzel J, DeLoughery TG. Hormonal therapies and venous thrombosis: considerations for prevention and management. Res Pract Thromb Haemost. 2022;6(6):e12763. Published 2022 Aug 23. https://doi.org/10.1002/rth2.12763.

36.

Curtis KM, Zapata LB, Pagano HP, Nguyen A, Reeves J, Whiteman MK. Removing unnecessary medical barriers to contraception: celebrating a decade of the U.S. Medical Eligibility Criteria for Contraceptive Use. J Womens Health (Larchmt). 2021;30(3):293–300. https://doi.org/10.1089/jwh.2020.8910.

37.

Serfaty D. Update on the contraceptive contraindications. J Gynecol Obstet Hum Reprod. 2019;48(5):297–307.CrossRefPubMed

38.

Gomez A, Walters P, Dao LT. “Testosterone in a way is birth control”: contraceptive attitudes and experiences among transmasculine and genderqueer young adults. Contraception. 2016;94:422–3.CrossRef

39.

Krempasky C, Harris M, Abern L, Grimstad F. Contraception across the transmasculine spectrum. Am J Obstet Gynecol. 2020;222:134–43.CrossRefPubMed

40.

Bates CK, Carroll N, Potter J. The challenging pelvic examination. J Gen Intern Med. 2011;26:651–7.CrossRefPubMedPubMedCentral

41.

Akgul S, Bonny AE, Ford N, Holland-Hall C, Chelvakumar G. Experiences of gender minority youth with the intrauterine system. J Adolesc Health. 2019;65(1):32–8. https://doi.org/10.1016/j.jadohealth.2018.11.010.CrossRefPubMed

42.

Hodax JK, Wagner J, Sackett-Taylor AC, Rafferty J, Forcier M. Medical options for care of gender diverse and transgender youth. J Pediatr Adolesc Gynecol. 2020;33:3–9.CrossRefPubMed

43.

Abern L, Krempasky C, Diego D, et al. The intrauterine device experience among transgender and gender-diverse individuals assigned female at birth. J Midwifery Womens Health. 2021;66(6):772–7. https://doi.org/10.1111/jmwh.13310.CrossRefPubMed

44.

• Berglin M, Stram D, Stenquist A, Dessi S, Ritterman Weintraub M, Zaritsky E. Intrauterine device, subdermal contraceptive, and depot medroxyprogesterone use among transmasculine and cisgender patients over a 10-year period. Contraception. 2022;108:56–60. https://doi.org/10.1016/j.contraception.2021.11.001. Findings from this study suggest that annual uptake of the intrauterine device, the subdermal contraceptive, and depot medroxyprogesterone has increased significantly in both transmasculine and cisgender individuals in the past 10 years, with a larger increase being shown for the transmasculine group.CrossRefPubMed

45.

Lavelanet AF, Rybin D, White KO. The pharmacokinetics of 12-week continuous contraceptive patch use. Contraception. 2017;95(6):578–85. https://doi.org/10.1016/j.contraception.2017.03.002. (Epub 2017 Mar 8 PMID: 28285154).CrossRefPubMed

46.

Meriggiola MC, Gava G. Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen. Clin Endocrinol (Oxf). 2015;83(5):607–615. https://doi.org/10.1111/cen.12754.

47.

Asscheman H, T’Sjoen G, Lemaire A, et al. Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review. Andrologia. 2014;46(7):791–5. https://doi.org/10.1111/and.12150.CrossRefPubMed

48.

Gava G, Meriggiola MC. Update on male hormonal contraception. Ther Adv Endocrinol Metab. 2019;10:2042018819834846. Published 2019 Mar 14. https://doi.org/10.1177/2042018819834846.

49.

Neblett MF 2nd, Hipp HS. Fertility considerations in transgender persons. Endocrinol Metab Clin North Am. 2019;48(2):391–402. https://doi.org/10.1016/j.ecl.2019.02.003.CrossRefPubMed

50.

Schneider F, Kliesch S, Schlatt S, Neuhaus N. Andrology of male-to-female transsexuals: influence of cross-sex hormone therapy on testicular function. Andrology. 2017;5(5):873–80. https://doi.org/10.1111/andr.12405.CrossRefPubMed

51.

Jindarak S, Nilprapha K, Atikankul T, et al. Spermatogenesis abnormalities following hormonal therapy in transwomen. Biomed Res Int. 2018;2018:7919481. Published 2018 Apr 2. https://doi.org/10.1155/2018/7919481.

52.

Matoso A, Khandakar B, Yuan S, et al. Spectrum of findings in orchiectomy specimens of persons undergoing gender confirmation surgery. Hum Pathol. 2018;76:91–9. https://doi.org/10.1016/j.humpath.2018.03.007.CrossRefPubMed

53.

Fainberg J, Kashanian JA. Vasectomy JAMA. 2018;319(23):2450. https://doi.org/10.1001/jama.2018.6514.CrossRefPubMed

54.

James SE, Herman JL, Rankin S, Keisling M, Mottet L, Anafi M. The report of the 2015 U.S. Transgender Survey. Washington, DC: National Center for Transgender Equality; 2016.

55.

American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice; American College of Obstetricians and Gynecologists’ Committee on Health Care for Underserved Women. Health Care for Transgender and Gender Diverse Individuals: ACOG Committee Opinion, Number 823. Obstet Gynecol. 2021;137(3):e75-e88. https://doi.org/10.1097/AOG.0000000000004294.

Titel: An Update on Contraception for Transgender, Non-binary, and Gender-expansive Individuals
verfasst von: Kelsey Mumford
Alexis Light
Publikationsdatum: 19.05.2023
Verlag: Springer US
Erschienen in: Current Obstetrics and Gynecology Reports / Ausgabe 2/2023
Elektronische ISSN: 2161-3303
DOI: https://doi.org/10.1007/s13669-023-00362-x

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

An Update on Contraception for Transgender, Non-binary, and Gender-expansive Individuals

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Fehlerkultur in der Medizin – Offenheit zählt!

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

Update Gynäkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Management of Labor and Delivery to Reduce Risk for Cesarean Birth in Women with Obesity

Congenital Anomalies in Women with Obesity

Pharmacologic Treatment of Obesity in Reproductive Aged Women

Preventing Adverse Cardiovascular Outcomes in Pregnancy Complicated by Obesity

Infertility Treatment in Women with Obesity

Considerations for Contraceptive Use Among Patients with Migraines

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Fehlerkultur in der Medizin – Offenheit zählt!

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

Update Gynäkologie